Lexicon Pharmaceuticals Inc
NASDAQ:LXRX
Intrinsic Value
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. [ Read More ]
The intrinsic value of one
LXRX
stock under the Base Case scenario is
5.23
USD.
Compared to the current market price of 1.79 USD,
Lexicon Pharmaceuticals Inc
is
Undervalued by 66%.
LXRX's market price has consistently been higher than its intrinsic value.This persistent overvaluation suggests the market may be overly optimistic about
LXRX or that its price is influenced by factors unrelated to fundamentals.
Lexicon Pharmaceuticals Inc's market capitalization is 440.8m USD.
LXRX stock price is 1.79 USD.
LXRX stock price (1.79 USD) is 66% less than its Intrinsic Value (5.23 USD).
LXRX. Open DCF Valuation
LXRX has upside potential of 199% compared to the average analyst price target.
Open Wall St Estimates
LXRX's ROE (Return on Equity) has significantly decreased in the last 3 years from -13% to -103%, and is approaching profitability.
LXRX's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -7% to -372%, and is approaching profitability.
LXRX has negative Operating Income for the last twelve months.
LXRX has negative Net Income for the last twelve months.
LXRX's ROE (Return on Equity) for the past 12 months is negative and is equal to -103%.
LXRX's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -372%.
LXRX has positive Gross Profit for the last twelve months.
LXRX's Revenue is forecast to grow at a rate of 425% per year over the next 3 years.
LXRX's D/E (Debt to Equity) is very low and is equal to 0.35.
LXRX has negative Free Cash Flow for the last twelve months.
LXRX's Revenue has been falling by 47% per year for the last 3 years.
LXRX's long-term assets (417m USD) exceed its long-term liabilties (128m USD).
LXRX has negative Net Debt. This means that the company has more cash and short-term investments (356m USD) than debt (100m USD).
LXRX has negative three-year average ROE (Return on Equity): -78%. The company is not efficient at transforming stockholders' equity into net income.
LXRX has negative three-year average ROIC (Return on Invested Capital): -228%. The company is not efficient at using invested capital to generate operating income.
LXRX's short-term assets (365m USD) exceed its short-term liabilties (23m USD).
LXRX's Altman Z-Score is very low and is equal to -4.83.
LXRX doesn't generate enough operating income (-186m USD) to safely cover interest payments on its debt (12m USD).
Valuation Backtest
Lexicon Pharmaceuticals Inc
Run backtest to discover the historical profit from buying and selling
LXRX
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Lexicon Pharmaceuticals Inc
Balance Sheet Decomposition
Lexicon Pharmaceuticals Inc
| Current Assets | 364.6m |
| Cash & Short-Term Investments | 355.6m |
| Receivables | 1.5m |
| Other Current Assets | 7.5m |
| Non-Current Assets | 52.6m |
| PP&E | 7.2m |
| Intangibles | 44.5m |
| Other Non-Current Assets | 828k |
| Current Liabilities | 23.4m |
| Accounts Payable | 8.1m |
| Accrued Liabilities | 11.5m |
| Other Current Liabilities | 3.9m |
| Non-Current Liabilities | 105m |
| Long-Term Debt | 99.9m |
| Other Non-Current Liabilities | 5.1m |
Earnings Waterfall
Lexicon Pharmaceuticals Inc
|
Revenue
|
2.3m
USD
|
|
Cost of Revenue
|
-101k
USD
|
|
Gross Profit
|
2.2m
USD
|
|
Operating Expenses
|
-188.1m
USD
|
|
Operating Income
|
-185.9m
USD
|
|
Other Expenses
|
-7.7m
USD
|
|
Net Income
|
-193.6m
USD
|
Free Cash Flow Analysis
Lexicon Pharmaceuticals Inc
LXRX Profitability Score
Profitability Due Diligence
Lexicon Pharmaceuticals Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
Score
Lexicon Pharmaceuticals Inc's profitability score is 18/100. The higher the profitability score, the more profitable the company is.
LXRX Solvency Score
Solvency Due Diligence
Lexicon Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Score
Lexicon Pharmaceuticals Inc's solvency score is 50/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LXRX Price Targets Summary
Lexicon Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for
LXRX
is 5.36 USD
with a low forecast of 2.02 USD and a high forecast of 10.5 USD.
Ownership
LXRX Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
LXRX Price
Lexicon Pharmaceuticals Inc
| Average Annual Return | -23.69% |
| Standard Deviation of Annual Returns | 27.39% |
| Max Drawdown | -89% |
| Market Capitalization | 440.8m USD |
| Shares Outstanding | 246 236 992 |
| Percentage of Shares Shorted | 42.17% |
Company Profile
Lexicon Pharmaceuticals Inc
Country
Industry
Market Cap
Dividend Yield
Description
Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company is headquartered in The Woodlands, Texas and currently employs 87 full-time employees. The company went IPO on 2000-04-07. The firm is focused on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its pipeline includes Sotagliflozin, LX9211, and LX2761. Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of heart failure and type I diabetes, and type II diabetes, heart failure and chronic kidney disease. LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The firm is conducting a Phase II clinical trial of LX9211 in diabetic peripheral neuropathic pain and a second Phase II clinical trial of LX9211 in post-herpetic neuralgia. LX2761 is an orally-delivered small molecule compound that is designed to inhibit sodium-glucose cotransporter 1 (SGLT1) locally in the gastrointestinal tract without any inhibition of sodium-glucose cotransporter 2 (SGLT2) in the kidney.
Contact
IPO
Employees
Officers
The intrinsic value of one
LXRX
stock under the Base Case scenario is
5.23
USD.
Compared to the current market price of 1.79 USD,
Lexicon Pharmaceuticals Inc
is
Undervalued by 66%.
You don't have any saved screeners yet
